Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

Merrimack Pharmaceuticals logo

About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$15.13
$15.13
50-Day Range
$14.65
$15.13
52-Week Range
$11.53
$15.89
Volume
N/A
Average Volume
396,929 shs
Market Capitalization
$223.77 million
P/E Ratio
1.09
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Remove Ads
Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

AI Boom Takes a Shocking Turn…
AI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a brand-new report…
See More Headlines

MACK Stock Analysis - Frequently Asked Questions

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) posted its quarterly earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.14.

Shares of Merrimack Pharmaceuticals reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Merrimack Pharmaceuticals' top institutional shareholders include MassMutual Private Wealth & Trust FSB (0.17%). Insiders that own company stock include Noah G Levy, Eric Andersen, Gary L Crocker and Ana Radeljevic.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Merrimack Pharmaceuticals investors own include Rite Aid (RAD), Agenus (AGEN), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
5/10/2019
Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MACK
Previous Symbol
NASDAQ:MACK
Employees
426
Year Founded
2000

Profitability

Trailing P/E Ratio
1.09
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.31 per share
Price / Book
11.55

Miscellaneous

Free Float
10,267,000
Market Cap
$223.77 million
Optionable
Optionable
Beta
1.45

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:MACK) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners